Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4 of KRAS and exons 2, 3 and 4 of a related gene, NRAS) may also be predictive of resistance.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann. Oncol.

Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

ISSN (Electronic): 1569-8041

ISSN (Print): 0923-7534

Publication date (Electronic): Jan 2015

Volume: 26

Issue: 1

Affiliations

[1 ] Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide michael.sorich@flinders.edu.au.

[2 ] School of Pharmacy and Medical Sciences, University of South Australia, Adelaide.

[3 ] Department of Clinical Pharmacology, School of Medicine, Flinders University, Adelaide.

[4 ] Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Adelaide, Australia.

Article

Publisher Item ID: mdu378

DOI: 10.1093/annonc/mdu378

PubMed ID: 25115304

SO-VID: 43766022-4221-4da0-94f8-011b5e33c391

Copyright © © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

History

Keywords: RAS mutation,cetuximab,meta-analysis,panitumumab,pharmacogenomics,predictive biomarker

Data availability:

Keywords: RAS mutation, cetuximab, meta-analysis, panitumumab, pharmacogenomics, predictive biomarker

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Read this article at

Abstract

Related collections

Road 2 Open Meta

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 50

Cited by 193